Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls
Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets
How this was made
The 30-second read
Why it matters
The mixed set of rating changes provides selective bullish signals but overall limited market-moving power.
Market read
The article aggregates rating actions, offering selective trade ideas but limited overall market impact.
What to watch
Potential impact of upcoming macro data (inflation, rates) could outweigh individual analyst actions.
Background
Analyst firms released a series of upgrades, downgrades, and new coverage initiations across a range of U.S. listed companies.
Ticker impact
Wolfe Research upgraded Paychex to Peer Perform, citing reduced estimate risk amid stable employment trends.
small upside
Upgrade reduces downside risk, may attract buyers.
UBS upgraded Union Pacific to Buy with a $339 price target, forecasting strong volume growth in 2027.
moderate upside
Higher target and growth outlook may drive demand.
Needham upgraded Rocket Pharmaceuticals to Buy after FDA reaffirmed pivotal study design for RP‑A501.
moderate upside
FDA reaffirmation reduces clinical risk.
Needham upgraded Similarweb to Buy, citing AI potential to increase data value.
small upside
Analyst sees AI as a catalyst.
JPMorgan upgraded Credicorp to Overweight, raising price target to $482.
moderate upside
Improved outlook despite regional risks.
Morgan Stanley downgraded Expedia to Underweight, citing weaker consumer assets and valuation premium.
downside risk
Analyst concerns on fundamentals and valuation.
Truist downgraded Meritage Homes to Hold, lowering price target to $72.
slight downside
Increased risk of incentive ramping.
Mizuho downgraded Hartford to Neutral, citing underwriting pressure and mix shift.
moderate downside
Profitability concerns may affect stock.
Market effects
Broad coverage upgrades/downgrades may slightly shift sentiment in consumer, tech, and financial sectors.
U.S. equities may see modest activity across multiple sectors.
Limited; primarily U.S. market focus.
Counterpoint
Many upgrades could be premature given macro headwinds; investors may wait for earnings confirmation.
Key entities
- analystWolfe Research
Upgraded Paychex
- analystUBS
Upgraded Union Pacific
- analystNeedham
Upgraded Rocket Pharmaceuticals and Similarweb
- analystJPMorgan
Upgraded Credicorp
- analystMorgan Stanley
Downgraded Expedia
